A Phase 1 interventional study of lipegfilgrastim in Pharmacokinetics and Pharmacodynamics, sponsored by Merckle GmbH. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Merckle GmbH · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Cohorts of Japanese participants will be enrolled and treated prior to cohorts of Caucasian participants for the sake of matching. Every effort will be made to match Caucasian and Japanese participants on a cohort basis at enrollment. Reasonable effort will be made to maintain balance between male and female participants within the cohorts. There will be no replacement of participants following randomization.
Eligible participants will be admitted to the investigational center and after confirming their eligibility will be randomized to receive a single dose of 30, 60, or 100 μg/kg lipegfilgrastim. There will be 11 visits to the investigational center during the study, including a screening visit, 1 inpatient period (through Day 4 post-dose) and 9 ambulatory visits.
Blood samples for PK, PD and immunogenicity analysis will be collected pre-dose and at specified time points post-dose. A mandatory blood sample for pharmacogenetics (PGx) will be collected from all participants. During the study the following safety assessments will be performed: vital signs measurements,physical examinations, record of adverse events, clinical laboratory tests, urinalysis, safety ECG recordings, local tolerability (injection site reactions), overall tolerability, pregnancy testing, spleen sonography, and concomitant medications
Merckle GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of must have a negative serum β-human chorionic gonadotropin (β-hCG) test at screening and negative urine pregnancy test at check-in. All subjects must be either surgically sterile (for females that means documented complete hysterectomy, bilateral oophorectomyor bi-tubal ligations; partial hysterectomy is not sufficient), abstinent throughout the study or, if of reproductive capacity and not abstinent, exercising any 2 different forms of highly effective methods with his/her partner during the entire study period.
o Additional inclusion criteria for Japanese subjects:
Subject has been living outside of Japan for 10 years or fewer as confirmed by interview.
o Additional inclusion criterion for Caucasian subjects:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lipegfilgrastim
Drug: lipegfilgrastim
Drug: lipegfilgrastim
lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
PK: Area under the serum concentration-time curve (AUC), from time 0 to the last measurable concentration (AUC0-t)
2 hours for visits 3, 9; 1 day for visit 10
Time frame: Days 1-8, 10, 14, 17, 21
AUC from time 0 extrapolated to infinity (AUC0-∞)
Time frame: Days 1-8, 10, 14, 17, 21
Maximum observed serum drug concentration (Cmax)
Time frame: Days 1-8, 10, 14, 17, 21
Time to maximum observed serum drug concentration (tmax)
Time frame: Days 1-8, 10, 14, 17, 21
The percentage of the extrapolated area to infinity in relation to the total area under the curve (%AUCext)
Time frame: Visits 3, 9, 10
Apparent serum terminal elimination rate constant (λz)
2 hours for visits 3, 9; 1 day for visit 10
Time frame: Days 1-8, 10, 14, 17, 21
Associated elimination half-life (t½)
Time frame: Days 1-8, 10, 14, 17, 21
Mean residence time (MRT)
Time frame: Days 1-8, 10, 14, 17, 21
Apparent total body clearance (CL/F)
Time frame: Days 1-8, 10, 14, 17, 21
Apparent volume of distribution during the terminal phase (Vz/F)
Time frame: Days 1-8, 10, 14, 17, 21
PD: ANC area over baseline effect curve (ANC AOBEC)
Time frame: Days 1-8, 10, 14, 17, 21
Maximum measured ANC value after dosing (ANC Cmax)
Time frame: Days 1-8, 10, 14, 17, 21
Time point at which ANC Cmax is observed (ANC tmax)
Time frame: Days 1-8, 10, 14, 17, 21
Time (days) until ANC returns to baseline value
Time frame: Days 1-8, 10, 14, 17, 21
CD34+ area over the baseline effect curve (CD34+ AOBEC)
Time frame: Days 1-8, 10, 14, 17, 21
Maximum measured CD34+ value after dosing (CD34+ Cmax)
Time frame: Days 1-8, 10, 14, 17, 21
Time point at which CD34+ Cmax is observed (CD34+ tmax)
Time frame: Days 1-8, 10, 14, 17, 21
Percentage of Participants with Adverse Events
Time frame: 28 Days
The record gives a start of Oct 2014, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim